Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations.

ABSTRACT:

Background

Human genetics is an important tool for identifying genes as potential drug targets, and the extensive genetic study of cardiovascular disease provides an opportunity to leverage genetics to match specific patient populations to specific drug targets to improve prioritization of patient selection for clinical studies.

Methods

We selected well described genetic variants in the region of PCSK9 (rs11591147 and rs562556), ADRB1 (rs7076938), ACE (rs4968782 and rs4363), GLP1R (rs10305492) and ABCC8 (rs757110) for use as proxies for the effects of drugs. Time-to-event analyses were utilized to evaluate their effects on atrial fibrillation (AF) and heart failure (HF) death and/or re-hospitalization using real-world longitudinal dataset. To mitigate the effect of confoundi

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12057189 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature